Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting –

– Encouraging signs of clinical activity at tolerable doses disclosed from ongoing Phase 1 clinical trial of WTX-330 –

Read more at globenewswire.com